{"schema_version":"secwatch.filing_event.v1","accession":"0000012208-23-000045","form_type":"8-K","ticker":"BIO","cik":"0000012208","company_name":"BIO-RAD LABORATORIES, INC.","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.186339+00:00","generated_at":"2026-06-15T20:43:52.067062+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Bio-Rad Q1 sales down 3.3% to $676.8M; operating income drops 57.7% to $61.9M","bullets":["Net sales $676.8M, down 3.3%; currency-neutral down 0.3%; ex-COVID up 6.1%.","GAAP diluted EPS $2.32 vs loss of $112.50; operating income $61.9M vs $146.4M.","Life Science sales $323.6M, down 6.8% (ex-COVID up 9.6% on qPCR, western blotting, ddPCR).","Clinical Diagnostics sales $352.1M flat; currency-neutral up 2.8% ex-COVID up 3.1%.","COVID sales dropped to $2.6M from $45M; gross margin fell to 53.5% from 57.5%."],"urls":{"canonical":"https://secwatch.observer/filing/0000012208-23-000045","json":"https://secwatch.observer/filing/0000012208-23-000045.json","markdown":"https://secwatch.observer/filing/0000012208-23-000045.md","text":"https://secwatch.observer/filing/0000012208-23-000045.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/12208/000001220823000045/0000012208-23-000045-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/12208/000001220823000045/bio-20230504.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T20:43:52.067062+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c99312868797cfd50dd00a083da7800ed7b3bc46","claim":"BIO-RAD LABORATORIES, INC. reported the first quarter ended March 31, 2023 results: revenue $676.8 million, net income $69 million, EPS $2.32 per diluted share.","evidence_excerpt":"First-quarter 2023 net sales were $676.8 million, a decrease of 3.3 percent compared to $700.1 million reported for the first quarter of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/12208/000001220823000045/0000012208-23-000045-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Revenue","value":"$676.8 million"},{"label":"Net income","value":"$69 million"},{"label":"EPS","value":"$2.32 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}